Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY) has added more products to its medical cannabis portfolio in the United Kingdom.
On Thursday, the company said its portfolio is now the broadest in cannabis flower in the U.K. market. The new SKUs will include high THC products spanning from 10-25 per cent in different ratios that were cultivated at its EU-GMP-certified facility in Portugal.
Tilray Medical says it hopes to expand the range of treatment options available and ensure prescribers and patients are provided with a safe and reliable choice as they embark on their medical cannabis journey.
Patients in the U.K. may obtain prescriptions for medical cannabis through their doctor.
Read more: Luxembourg health authorities visit Tilray Medical facilities in Portugal
Read more: Tilray Medical launches CBN oil for sleep
“The demand for medical cannabis in the UK is growing rapidly. We are incredibly proud to provide patients in the UK with high-quality, consistent medical cannabis products they can rely on and are accessible to them,” Tilray CSO Denise Faltischek said.
Tilray Medical owns the brands Tilray, Aphria, Broken Coast and Symbios. It is one of the first companies to become an approved licensed producer of cannabis in Canada and among the first to build EU-GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany.
Its Tilray Medical is one of the biggest suppliers of medical cannabis brands in 20 countries and across five continents. The medical division includes Tilray Medical Canada, Tilray Medical Australia, Tilray Medical Australia-New Zealand and Tilray Medical Europe.
Company stock went down on Thursday by 6.09 per cent to $4.01 on the Toronto Securities Exchange.
